Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1201-1206

  Matsumoto, Gaku ^a   Nagai, Shigenori ^a   Muta, Mariko ^a   Tsuruta, Koji ^a   Okamoto, Atsutake ^a   Toi, Masakazu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Hamster; KRN7000; Liver metastases model; NKT cell; Pancreatic cancer; TNP470

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ANTINEOPLASTIC ANTIBIOTIC; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOHEXANE DERIVATIVE; FUMAGILLOL CHLOROACETYLCARBAMATE; GALACTOSYLCERAMIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIVISION; DISEASE MODEL; HAMSTER; IMMUNOTHERAPY; LIVER; LIVER TUMOR; MALE; METABOLISM; METASTASIS; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYRIAN HAMSTER; TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD4; ANTIGENS, CD8; CELL DIVISION; CRICETINAE; CYCLOHEXANES; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; IMMUNOTHERAPY; INTERFERON TYPE II; LIVER; LIVER NEOPLASMS; MALE; MESOCRICETUS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SESQUITERPENES; TIME FACTORS;

EID: 2142745358     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1201     Document Type: Article

References (46)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000. (Pubitemid 30072093)
2. Yeo CJ, Cameron JI, Sohn TA, et al: Pancreaticoduodenectomy for cancer of the pancreas: 201 patients. Ann Surg 22: 721-733, 1995.
3. Ishikawa O, Ohigashi H, Sasaki Y, et al: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208: 215-220, 1988.
4. Westerdahl J, Andren-Sandberg A and Ihse I: Recurrence of exocrine pancreatic cancer-local or hepatic? Hepatogastroenterology 40: 384-387, 1993. (Pubitemid 23258561)
5. Taylor I: Should further studies of chemotherapy be carried out in pancreatic cancer? Eur I Cancer 29A: 1078-1081, 1993.
6. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP and Harris AL: The relationship between angiogenesis and immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36: 151-169, 2000. (Pubitemid 30102191)
7. Kawano T, Cui J, Koezuka Y, et al: CD Id-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629, 1997. (Pubitemid 27516282)
8. Porcelli SA, Segelke BW, Sugita M, Wilson IA and Brenner MB: The CD1 family of lipid antigen-presenting molecules. Immunol Today 19: 362-368, 1998.
9. + NK T lymphocytes. J Immunol 161: 3271-3281, 1998.
10. + T cell populations. Int Immunol 7: 1157-1161, 1995.
11. --T cells in mice and humans. J Exp Med 180: 1097-1106, 1994.
12. + T cells upon NKR-P1 crosslinking. J Exp Med 183: 2391-2396, 1996.
13. Kawano T, Cui J, Koezuka Y, et al: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V alpha 14 NKT cells. Proc Natl Acad Sci USA 95: 5690-5693, 1998. (Pubitemid 28224157)
14. Nakagawa R, Motoki K, Ueno H, et al: Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000. Cancer Res 15: 1202-1207, 1998. (Pubitemid 28183209)
15. Nakagawa R, Motoki K, Nakamura H, et al: Antitumor activity of α-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 10: 561-568, 1998.
16. Toura I, Kawana T, Akutsu Y, Nakayama T, Ochiai T and Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 163: 2387-2391, 1999. (Pubitemid 29399156)
17. Van der Vliet HJJ, Nishi N, Koezuka Y, et al: Effects of α-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Vα24+ Vβ11+ T cells. Immunology 98: 557-563, 1999. (Pubitemid 30005337)
18. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H and Folkman J: Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557, 1990. (Pubitemid 120015110)
19. Sin N, Meng L, Wang MQW, Wen JJ, Bornmann WG and Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionin aminipeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099-6103, 1997. (Pubitemid 27270643)
20. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M and Takuwa Y: A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54: 3407-3412, 1994.
21. Yosida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M and Kimura S: Suppression of hepatoma growth and angiogenesis by fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 58: 3751-3756, 1998. (Pubitemid 28376579)
22. Tanaka T, Konno H, Matsuda I, Nakamura S and Baba S: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 15: 836-839, 1995.
23. Kawarada Y, Ishikura H, Kishimoto T, Saito K, Takahashi T, Kato H and Yoshiki T: Inhibitory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas 15: 251-257, 1997. (Pubitemid 27524674)
24. Ahmed MH, Konno H, Nahar L, Tanaka T, Naito Y, Nakamura S and Baba S: The angiogenesis inhibitor TNP-470(AGM-1470) improves long-term survival of rats with liver metastasis. J Surg Res 64: 35-41, 1996. (Pubitemid 26268726)
25. Tanaka H, Taniguchi H, Mugitani T, et al: Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing. Br J Surg 83: 1444-1447, 1996. (Pubitemid 26342181)
26. Kudelka AP, Verschraegen CF and Loyer E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 338: 991-992, 1998. (Pubitemid 28152844)
27. Antoine N, Daukandt M, Heinen E, Simar LJ and Castronovo V: In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Am J Pathol 148: 393-398, 1996. (Pubitemid 26056724)
28. Locigno R, Antoine N, Bours V, Daukandt M, Heinen E and Castronovo V: TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-κB, nuclear factor-AT, and activation protein-1 transcription factors. Lab Invest 80: 13-21, 2000. (Pubitemid 30067375)
29. Mori T, Tsutsumi M, Noguchi O, et al: Characterization of three cloned cell lines from a N-nitrosobis (2-hydroxypropyl) amine-induced transplantable hamster pancreatic ductal adenocarcinoma. Int J Pancreatol 16: 171-177, 1994. (Pubitemid 24337844)
30. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 156: 3366-3373 1996.
31. Kopper L, van Hanh T and Lapis K: Experimental model for liver metastasis formation using Lewis lung tumor. J Cancer Res Clin Oncol 103:31-38, 1982. (Pubitemid 12132313)
32. Egawa S, Tsutsumi M, Konishi Y, et al: The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology 108: 1526-1533, 1995.
33. Yanagi K, Onda M and Uchida E: Effect of angiostatin of liver metastasis of pancreatic cancer in hamsters. Jpn J Cancer Res 91: 723-730, 2000. (Pubitemid 30612357)
34. Fuji N, Ueda Y, Fujiwara H, Itoh T, Yoshimura T and Yamagishi H: Antitumor effect of α-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 6: 3380-3387, 2000. (Pubitemid 30637770)
35. Szente BE, Weiner IJ, Jablonsky MJ, Krishna NR, Torres BA and Johnson HM: Structural requirements for agonist activity of a murine interferon-γ peptide. J Interferon Cytokine Res 16: 813-817, 1996. (Pubitemid 26389119)
36. Lundell D, Lunn C, Dalgarno D, et al: The carboxyl-terminal region of human interferon γ is important for biological activity: mutagenic and NMR analysis. Protein Eng 4: 335-343, 1991.
37. Lundell DC, Lunn A, Senior MM, Zavodny PJ and Narula SK: Importance of the loop connecting A and B helices of human interferon-γ in recognition by interferon-y receptor. J Biol Chem 269: 16159-16162, 1994. (Pubitemid 24209306)
38. Carvalho EM, Teixeira RS and Johnson WD Jr: Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 33: 498-500, 1981.
39. Carvalho EM, Badaro R, Reed SG, Jones TC and Johnson WD Jr: Absence of γ interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 2066-2069, 1985. (Pubitemid 16155495)
40. Melby PC, Chandrasekar B, Zhao W and Coe JE: The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166: 1912-1920, 2001. (Pubitemid 32114678)
41. Stenger SH, Thuring H, Rollinghoff M and Bogdan C: Tissue expression of inducible nitric oxide synthase is closely associated with resistance to leishmania major. J Exp Med 180: 783-793, 1994. (Pubitemid 24256592)
42. Zhang X, Laubach VE, Alley EW, Edwards KA, Sherman PA, Russell SW and Murphy WJ: Transcriptional basis for hyporesponsiveness of the human inducible nitric oxide synthase gene to lipopolysaccharide/interferon-γ. J Leukoc Biol 59: 575-585, 1996.
43. Giaccone G, Punt CJA, Ando Y, et al: A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709, 2002. (Pubitemid 35424759)
44. Nakagawa R, Sekizawa I, Motoki K, et al: Antitumor activity of α-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol Res 12: 51-58, 2000.
45. Smyth MJ and Godfry DI: NKT cells and tumor immunity - a double-edged sword. Nat Immunol 1: 459-460, 2000.
46. Matsuda JL, Naidenko OV, Gapin L, et al: Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 192: 741-754, 2000.